ARTICLE | Clinical News
Tau Therapeutics preclinical data
May 5, 2014 7:00 AM UTC
In mouse xenograft models of K-Ras ( KRAS)-mutant pancreatic ductal adenocarcinomas, combination treatment with mibefradil plus trametinib led to greater inhibition of tumor growth compared to either treatment alone. Additionally, combination treatment led to near complete growth inhibition of KRAS-mutant tumors previously resistant to chronic trametinib therapy. Data were presented at the American Association for Cancer Research meeting in San Diego. ...